On Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened lower -3.88% from the last session, before settling in for the closing price of $279.82. Price fluctuations for ALNY have ranged from $141.98 to $304.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 97.61% over the last five years. Company’s average yearly earnings per share was noted 43.96% at the time writing. With a float of $127.83 million, this company’s outstanding shares have now reached $128.98 million.
The firm has a total of 2100 workers. Let’s measure their productivity. In terms of profitability, gross margin is 88.86%, operating margin of -9.34%, and the pretax margin is -15.94%.
Alnylam Pharmaceuticals Inc (ALNY) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Alnylam Pharmaceuticals Inc is 0.90%, while institutional ownership is 92.46%. The most recent insider transaction that took place on Aug 20 ’24, was worth 4,200,000. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $280.00, taking the stock ownership to the 73,441 shares. Before that another transaction happened on Aug 20 ’24, when Company’s Officer proposed sale 15,000 for $280.00, making the entire transaction worth $4,200,000.
Alnylam Pharmaceuticals Inc (ALNY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 43.96% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Check out the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). In the past quarter, the stock posted a quick ratio of 2.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.56. Likewise, its price to free cash flow for the trailing twelve months is 2159.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.62, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Analysing the last 5-days average volume posted by the [Alnylam Pharmaceuticals Inc, ALNY], we can find that recorded value of 0.97 million was better than the volume posted last year of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 48.92%. Additionally, its Average True Range was 8.92.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 62.76%, which indicates a significant increase from 14.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.81% in the past 14 days, which was lower than the 60.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $274.82, while its 200-day Moving Average is $209.36. Now, the first resistance to watch is $271.78. This is followed by the second major resistance level at $274.60. The third major resistance level sits at $278.44. If the price goes on to break the first support level at $265.12, it is likely to go to the next support level at $261.28. Now, if the price goes above the second support level, the third support stands at $258.46.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are currently 128,981K shares outstanding in the company with a market cap of 34.69 billion. Presently, the company’s annual sales total 1,828 M according to its annual income of -440,240 K. Last quarter, the company’s sales amounted to 500,920 K and its income totaled -111,570 K.
